Global Penile Cancer Market
Global Penile Cancer Market

Penile Cancer Comprehensive Study by Diagnostic Test Type (Biopsy, Ultrasound, Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI))), Penile Cancer Type (Epidermoid/squamous cell carcinoma, Basal cell carcinoma, Melanoma, Sarcoma), Therapy Type (Radiation Therapy, Chemotherapy, Biological Therapy, Surgery (Cryosurgery, Laser Surgery)), Cause (Human Papiloma Virus (HPV), Human Immunodeficiency Virus (HIV), Others), Grade (Grade x, Grade 1, Grade 2, Grade 3) Players and Region - Global Market Outlook to 2024

Penile Cancer Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 244 Pages 199 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Penile Cancer Market Scope
Penile cancer is one of the rare forms of cancer that is generally caused due to human papiloma virus (HPV) and human immunodeficiency virus (HIV). It has been observed that penile cancer generally causes in a higher age (more than 35age). Many regional governments have been taking many initiatives to reduce penile cancer by giving proper education about penile cancer and the importance of being hygienic. Availability of personalized medicine & cost-effective treatment procedures is supplementing overall growth of the market. Additionally, continuously increasing research and development activities by government and key players, increasing poor hygienic people in many geographical regions can create a new opportunity for the market. However, lack of standard in reimbursement policies, low literacy rate and lack of awareness among people is limiting the growth of the market.

The market study is being classified and major geographies with country level break-up.

The Players having a strong hold in the market are GlaxoSmithKline, Novartis AG, MercK & Co, Mevion Medical Systems, Inc.. Research Analyst at AMA predicts that United States and Switzerland Players will contribute to the maximum growth of Global Penile Cancer market throughout the predicted period.

GlaxoSmithKline (United States), Novartis AG (Switzerland), MercK & Co (United States), Mevion Medical Systems, Inc. (United States), Varian Medical Systems, Inc. (United States) and Pfizer Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol-Myers Squibb Company (United States) and F. Hoffmann-La Roche Ltd (Switzerland).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Penile Cancer market by Type, Application and Region.

On the basis of geography, the market of Penile Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnostic Test Type, the sub-segment i.e. Biopsy will boost the Penile Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Penile Cancer Type, the sub-segment i.e. Epidermoid/squamous cell carcinoma will boost the Penile Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Type, the sub-segment i.e. Radiation Therapy will boost the Penile Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cause, the sub-segment i.e. Human Papiloma Virus (HPV) will boost the Penile Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Grade, the sub-segment i.e. Grade x will boost the Penile Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 22 January 2019, GlaxoSmithKline plc had acquired TESARO (Biopharmaceutical Company) in approximately 5.1 billion. The transaction has done on 3 December 2018. The acquisition has done to expand the biopharmaceutical business of the GlaxoSmithKline plc.



Market Trend
  • Increasing Use of Targeted Therapy for Penile Cancer in Last Stage

Market Drivers
  • Increasing Penile Cancer Incidents particularly in North America and Europe
  • Availability of Personalized Medicine & Cost Effective Treatment Procedures

Opportunities
  • Continuously Increasing Research and Development Activities by Government and Key Players
  • Increasing Poor hygienic people in many geographical regional
  • Presence of Large HIV Patient Population

Restraints
  • Lack of Standard in Reimbursement Policies
  • Low Availability of Drug for Penile Cancer Treatment

Challenges
  • Low Literacy Rate and Lack of Awareness among People


Key Target Audience
Penile Cancer Treatment Service Provider, Penile Cancer Medicine Producer, Inventor, Private Research Organization, Government Bodies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Diagnostic Test Type
  • Biopsy
  • Ultrasound
  • Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI))

By Penile Cancer Type
  • Epidermoid/squamous cell carcinoma
  • Basal cell carcinoma
  • Melanoma
  • Sarcoma

By Therapy Type
  • Radiation Therapy
  • Chemotherapy
  • Biological Therapy
  • Surgery (Cryosurgery, Laser Surgery)

By Cause
  • Human Papiloma Virus (HPV)
  • Human Immunodeficiency Virus (HIV)
  • Others

By Grade
  • Grade x
  • Grade 1
  • Grade 2
  • Grade 3

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Penile Cancer Incidents particularly in North America and Europe
      • 3.2.2. Availability of Personalized Medicine & Cost Effective Treatment Procedures
    • 3.3. Market Challenges
      • 3.3.1. Low Literacy Rate and Lack of Awareness among People
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Targeted Therapy for Penile Cancer in Last Stage
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Penile Cancer, by Diagnostic Test Type, Penile Cancer Type, Therapy Type, Cause, Grade and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Penile Cancer (Value)
      • 5.2.1. Global Penile Cancer by: Diagnostic Test Type (Value)
        • 5.2.1.1. Biopsy
        • 5.2.1.2. Ultrasound
        • 5.2.1.3. Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI))
      • 5.2.2. Global Penile Cancer by: Penile Cancer Type (Value)
        • 5.2.2.1. Epidermoid/squamous cell carcinoma
        • 5.2.2.2. Basal cell carcinoma
        • 5.2.2.3. Melanoma
        • 5.2.2.4. Sarcoma
      • 5.2.3. Global Penile Cancer by: Therapy Type (Value)
        • 5.2.3.1. Radiation Therapy
        • 5.2.3.2. Chemotherapy
        • 5.2.3.3. Biological Therapy
        • 5.2.3.4. Surgery (Cryosurgery, Laser Surgery)
      • 5.2.4. Global Penile Cancer by: Cause (Value)
        • 5.2.4.1. Human Papiloma Virus (HPV)
        • 5.2.4.2. Human Immunodeficiency Virus (HIV)
        • 5.2.4.3. Others
      • 5.2.5. Global Penile Cancer by: Grade (Value)
        • 5.2.5.1. Grade x
        • 5.2.5.2. Grade 1
        • 5.2.5.3. Grade 2
        • 5.2.5.4. Grade 3
      • 5.2.6. Global Penile Cancer Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Penile Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. MercK & Co (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mevion Medical Systems, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Varian Medical Systems, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Penile Cancer Sale, by Diagnostic Test Type, Penile Cancer Type, Therapy Type, Cause, Grade and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Penile Cancer (Value)
      • 7.2.1. Global Penile Cancer by: Diagnostic Test Type (Value)
        • 7.2.1.1. Biopsy
        • 7.2.1.2. Ultrasound
        • 7.2.1.3. Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI))
      • 7.2.2. Global Penile Cancer by: Penile Cancer Type (Value)
        • 7.2.2.1. Epidermoid/squamous cell carcinoma
        • 7.2.2.2. Basal cell carcinoma
        • 7.2.2.3. Melanoma
        • 7.2.2.4. Sarcoma
      • 7.2.3. Global Penile Cancer by: Therapy Type (Value)
        • 7.2.3.1. Radiation Therapy
        • 7.2.3.2. Chemotherapy
        • 7.2.3.3. Biological Therapy
        • 7.2.3.4. Surgery (Cryosurgery, Laser Surgery)
      • 7.2.4. Global Penile Cancer by: Cause (Value)
        • 7.2.4.1. Human Papiloma Virus (HPV)
        • 7.2.4.2. Human Immunodeficiency Virus (HIV)
        • 7.2.4.3. Others
      • 7.2.5. Global Penile Cancer by: Grade (Value)
        • 7.2.5.1. Grade x
        • 7.2.5.2. Grade 1
        • 7.2.5.3. Grade 2
        • 7.2.5.4. Grade 3
      • 7.2.6. Global Penile Cancer Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Penile Cancer: by Diagnostic Test Type(USD Million)
  • Table 2. Penile Cancer Biopsy , by Region USD Million (2013-2018)
  • Table 3. Penile Cancer Ultrasound , by Region USD Million (2013-2018)
  • Table 4. Penile Cancer Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI)) , by Region USD Million (2013-2018)
  • Table 5. Penile Cancer: by Penile Cancer Type(USD Million)
  • Table 6. Penile Cancer Epidermoid/squamous cell carcinoma , by Region USD Million (2013-2018)
  • Table 7. Penile Cancer Basal cell carcinoma , by Region USD Million (2013-2018)
  • Table 8. Penile Cancer Melanoma , by Region USD Million (2013-2018)
  • Table 9. Penile Cancer Sarcoma , by Region USD Million (2013-2018)
  • Table 10. Penile Cancer: by Therapy Type(USD Million)
  • Table 11. Penile Cancer Radiation Therapy , by Region USD Million (2013-2018)
  • Table 12. Penile Cancer Chemotherapy , by Region USD Million (2013-2018)
  • Table 13. Penile Cancer Biological Therapy , by Region USD Million (2013-2018)
  • Table 14. Penile Cancer Surgery (Cryosurgery, Laser Surgery) , by Region USD Million (2013-2018)
  • Table 15. Penile Cancer: by Cause(USD Million)
  • Table 16. Penile Cancer Human Papiloma Virus (HPV) , by Region USD Million (2013-2018)
  • Table 17. Penile Cancer Human Immunodeficiency Virus (HIV) , by Region USD Million (2013-2018)
  • Table 18. Penile Cancer Others , by Region USD Million (2013-2018)
  • Table 19. Penile Cancer: by Grade(USD Million)
  • Table 20. Penile Cancer Grade x , by Region USD Million (2013-2018)
  • Table 21. Penile Cancer Grade 1 , by Region USD Million (2013-2018)
  • Table 22. Penile Cancer Grade 2 , by Region USD Million (2013-2018)
  • Table 23. Penile Cancer Grade 3 , by Region USD Million (2013-2018)
  • Table 24. South America Penile Cancer, by Country USD Million (2013-2018)
  • Table 25. South America Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 26. South America Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 27. South America Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 28. South America Penile Cancer, by Cause USD Million (2013-2018)
  • Table 29. South America Penile Cancer, by Grade USD Million (2013-2018)
  • Table 30. Brazil Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 31. Brazil Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 32. Brazil Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 33. Brazil Penile Cancer, by Cause USD Million (2013-2018)
  • Table 34. Brazil Penile Cancer, by Grade USD Million (2013-2018)
  • Table 35. Argentina Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 36. Argentina Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 37. Argentina Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 38. Argentina Penile Cancer, by Cause USD Million (2013-2018)
  • Table 39. Argentina Penile Cancer, by Grade USD Million (2013-2018)
  • Table 40. Rest of South America Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 41. Rest of South America Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 42. Rest of South America Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 43. Rest of South America Penile Cancer, by Cause USD Million (2013-2018)
  • Table 44. Rest of South America Penile Cancer, by Grade USD Million (2013-2018)
  • Table 45. Asia Pacific Penile Cancer, by Country USD Million (2013-2018)
  • Table 46. Asia Pacific Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 47. Asia Pacific Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 48. Asia Pacific Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 49. Asia Pacific Penile Cancer, by Cause USD Million (2013-2018)
  • Table 50. Asia Pacific Penile Cancer, by Grade USD Million (2013-2018)
  • Table 51. China Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 52. China Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 53. China Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 54. China Penile Cancer, by Cause USD Million (2013-2018)
  • Table 55. China Penile Cancer, by Grade USD Million (2013-2018)
  • Table 56. Japan Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 57. Japan Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 58. Japan Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 59. Japan Penile Cancer, by Cause USD Million (2013-2018)
  • Table 60. Japan Penile Cancer, by Grade USD Million (2013-2018)
  • Table 61. India Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 62. India Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 63. India Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 64. India Penile Cancer, by Cause USD Million (2013-2018)
  • Table 65. India Penile Cancer, by Grade USD Million (2013-2018)
  • Table 66. South Korea Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 67. South Korea Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 68. South Korea Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 69. South Korea Penile Cancer, by Cause USD Million (2013-2018)
  • Table 70. South Korea Penile Cancer, by Grade USD Million (2013-2018)
  • Table 71. Taiwan Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 72. Taiwan Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 73. Taiwan Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 74. Taiwan Penile Cancer, by Cause USD Million (2013-2018)
  • Table 75. Taiwan Penile Cancer, by Grade USD Million (2013-2018)
  • Table 76. Australia Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 77. Australia Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 78. Australia Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 79. Australia Penile Cancer, by Cause USD Million (2013-2018)
  • Table 80. Australia Penile Cancer, by Grade USD Million (2013-2018)
  • Table 81. Rest of Asia-Pacific Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 82. Rest of Asia-Pacific Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 83. Rest of Asia-Pacific Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 84. Rest of Asia-Pacific Penile Cancer, by Cause USD Million (2013-2018)
  • Table 85. Rest of Asia-Pacific Penile Cancer, by Grade USD Million (2013-2018)
  • Table 86. Europe Penile Cancer, by Country USD Million (2013-2018)
  • Table 87. Europe Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 88. Europe Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 89. Europe Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 90. Europe Penile Cancer, by Cause USD Million (2013-2018)
  • Table 91. Europe Penile Cancer, by Grade USD Million (2013-2018)
  • Table 92. Germany Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 93. Germany Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 94. Germany Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 95. Germany Penile Cancer, by Cause USD Million (2013-2018)
  • Table 96. Germany Penile Cancer, by Grade USD Million (2013-2018)
  • Table 97. France Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 98. France Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 99. France Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 100. France Penile Cancer, by Cause USD Million (2013-2018)
  • Table 101. France Penile Cancer, by Grade USD Million (2013-2018)
  • Table 102. Italy Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 103. Italy Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 104. Italy Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 105. Italy Penile Cancer, by Cause USD Million (2013-2018)
  • Table 106. Italy Penile Cancer, by Grade USD Million (2013-2018)
  • Table 107. United Kingdom Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 108. United Kingdom Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 109. United Kingdom Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 110. United Kingdom Penile Cancer, by Cause USD Million (2013-2018)
  • Table 111. United Kingdom Penile Cancer, by Grade USD Million (2013-2018)
  • Table 112. Netherlands Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 113. Netherlands Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 114. Netherlands Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 115. Netherlands Penile Cancer, by Cause USD Million (2013-2018)
  • Table 116. Netherlands Penile Cancer, by Grade USD Million (2013-2018)
  • Table 117. Rest of Europe Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 118. Rest of Europe Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 119. Rest of Europe Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 120. Rest of Europe Penile Cancer, by Cause USD Million (2013-2018)
  • Table 121. Rest of Europe Penile Cancer, by Grade USD Million (2013-2018)
  • Table 122. MEA Penile Cancer, by Country USD Million (2013-2018)
  • Table 123. MEA Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 124. MEA Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 125. MEA Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 126. MEA Penile Cancer, by Cause USD Million (2013-2018)
  • Table 127. MEA Penile Cancer, by Grade USD Million (2013-2018)
  • Table 128. Middle East Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 129. Middle East Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 130. Middle East Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 131. Middle East Penile Cancer, by Cause USD Million (2013-2018)
  • Table 132. Middle East Penile Cancer, by Grade USD Million (2013-2018)
  • Table 133. Africa Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 134. Africa Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 135. Africa Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 136. Africa Penile Cancer, by Cause USD Million (2013-2018)
  • Table 137. Africa Penile Cancer, by Grade USD Million (2013-2018)
  • Table 138. North America Penile Cancer, by Country USD Million (2013-2018)
  • Table 139. North America Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 140. North America Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 141. North America Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 142. North America Penile Cancer, by Cause USD Million (2013-2018)
  • Table 143. North America Penile Cancer, by Grade USD Million (2013-2018)
  • Table 144. United States Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 145. United States Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 146. United States Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 147. United States Penile Cancer, by Cause USD Million (2013-2018)
  • Table 148. United States Penile Cancer, by Grade USD Million (2013-2018)
  • Table 149. Canada Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 150. Canada Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 151. Canada Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 152. Canada Penile Cancer, by Cause USD Million (2013-2018)
  • Table 153. Canada Penile Cancer, by Grade USD Million (2013-2018)
  • Table 154. Mexico Penile Cancer, by Diagnostic Test Type USD Million (2013-2018)
  • Table 155. Mexico Penile Cancer, by Penile Cancer Type USD Million (2013-2018)
  • Table 156. Mexico Penile Cancer, by Therapy Type USD Million (2013-2018)
  • Table 157. Mexico Penile Cancer, by Cause USD Million (2013-2018)
  • Table 158. Mexico Penile Cancer, by Grade USD Million (2013-2018)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Penile Cancer: by Diagnostic Test Type(USD Million)
  • Table 166. Penile Cancer Biopsy , by Region USD Million (2019-2024)
  • Table 167. Penile Cancer Ultrasound , by Region USD Million (2019-2024)
  • Table 168. Penile Cancer Imaging Tests (Computed Tomography (CT), Position Emission Tomography (PET), Magnetic Resonance Imaging (MRI)) , by Region USD Million (2019-2024)
  • Table 169. Penile Cancer: by Penile Cancer Type(USD Million)
  • Table 170. Penile Cancer Epidermoid/squamous cell carcinoma , by Region USD Million (2019-2024)
  • Table 171. Penile Cancer Basal cell carcinoma , by Region USD Million (2019-2024)
  • Table 172. Penile Cancer Melanoma , by Region USD Million (2019-2024)
  • Table 173. Penile Cancer Sarcoma , by Region USD Million (2019-2024)
  • Table 174. Penile Cancer: by Therapy Type(USD Million)
  • Table 175. Penile Cancer Radiation Therapy , by Region USD Million (2019-2024)
  • Table 176. Penile Cancer Chemotherapy , by Region USD Million (2019-2024)
  • Table 177. Penile Cancer Biological Therapy , by Region USD Million (2019-2024)
  • Table 178. Penile Cancer Surgery (Cryosurgery, Laser Surgery) , by Region USD Million (2019-2024)
  • Table 179. Penile Cancer: by Cause(USD Million)
  • Table 180. Penile Cancer Human Papiloma Virus (HPV) , by Region USD Million (2019-2024)
  • Table 181. Penile Cancer Human Immunodeficiency Virus (HIV) , by Region USD Million (2019-2024)
  • Table 182. Penile Cancer Others , by Region USD Million (2019-2024)
  • Table 183. Penile Cancer: by Grade(USD Million)
  • Table 184. Penile Cancer Grade x , by Region USD Million (2019-2024)
  • Table 185. Penile Cancer Grade 1 , by Region USD Million (2019-2024)
  • Table 186. Penile Cancer Grade 2 , by Region USD Million (2019-2024)
  • Table 187. Penile Cancer Grade 3 , by Region USD Million (2019-2024)
  • Table 188. South America Penile Cancer, by Country USD Million (2019-2024)
  • Table 189. South America Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 190. South America Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 191. South America Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 192. South America Penile Cancer, by Cause USD Million (2019-2024)
  • Table 193. South America Penile Cancer, by Grade USD Million (2019-2024)
  • Table 194. Brazil Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 195. Brazil Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 196. Brazil Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 197. Brazil Penile Cancer, by Cause USD Million (2019-2024)
  • Table 198. Brazil Penile Cancer, by Grade USD Million (2019-2024)
  • Table 199. Argentina Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 200. Argentina Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 201. Argentina Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 202. Argentina Penile Cancer, by Cause USD Million (2019-2024)
  • Table 203. Argentina Penile Cancer, by Grade USD Million (2019-2024)
  • Table 204. Rest of South America Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 205. Rest of South America Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 206. Rest of South America Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 207. Rest of South America Penile Cancer, by Cause USD Million (2019-2024)
  • Table 208. Rest of South America Penile Cancer, by Grade USD Million (2019-2024)
  • Table 209. Asia Pacific Penile Cancer, by Country USD Million (2019-2024)
  • Table 210. Asia Pacific Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 211. Asia Pacific Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 212. Asia Pacific Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 213. Asia Pacific Penile Cancer, by Cause USD Million (2019-2024)
  • Table 214. Asia Pacific Penile Cancer, by Grade USD Million (2019-2024)
  • Table 215. China Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 216. China Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 217. China Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 218. China Penile Cancer, by Cause USD Million (2019-2024)
  • Table 219. China Penile Cancer, by Grade USD Million (2019-2024)
  • Table 220. Japan Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 221. Japan Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 222. Japan Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 223. Japan Penile Cancer, by Cause USD Million (2019-2024)
  • Table 224. Japan Penile Cancer, by Grade USD Million (2019-2024)
  • Table 225. India Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 226. India Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 227. India Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 228. India Penile Cancer, by Cause USD Million (2019-2024)
  • Table 229. India Penile Cancer, by Grade USD Million (2019-2024)
  • Table 230. South Korea Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 231. South Korea Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 232. South Korea Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 233. South Korea Penile Cancer, by Cause USD Million (2019-2024)
  • Table 234. South Korea Penile Cancer, by Grade USD Million (2019-2024)
  • Table 235. Taiwan Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 236. Taiwan Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 237. Taiwan Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 238. Taiwan Penile Cancer, by Cause USD Million (2019-2024)
  • Table 239. Taiwan Penile Cancer, by Grade USD Million (2019-2024)
  • Table 240. Australia Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 241. Australia Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 242. Australia Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 243. Australia Penile Cancer, by Cause USD Million (2019-2024)
  • Table 244. Australia Penile Cancer, by Grade USD Million (2019-2024)
  • Table 245. Rest of Asia-Pacific Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 246. Rest of Asia-Pacific Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 247. Rest of Asia-Pacific Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 248. Rest of Asia-Pacific Penile Cancer, by Cause USD Million (2019-2024)
  • Table 249. Rest of Asia-Pacific Penile Cancer, by Grade USD Million (2019-2024)
  • Table 250. Europe Penile Cancer, by Country USD Million (2019-2024)
  • Table 251. Europe Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 252. Europe Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 253. Europe Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 254. Europe Penile Cancer, by Cause USD Million (2019-2024)
  • Table 255. Europe Penile Cancer, by Grade USD Million (2019-2024)
  • Table 256. Germany Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 257. Germany Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 258. Germany Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 259. Germany Penile Cancer, by Cause USD Million (2019-2024)
  • Table 260. Germany Penile Cancer, by Grade USD Million (2019-2024)
  • Table 261. France Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 262. France Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 263. France Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 264. France Penile Cancer, by Cause USD Million (2019-2024)
  • Table 265. France Penile Cancer, by Grade USD Million (2019-2024)
  • Table 266. Italy Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 267. Italy Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 268. Italy Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 269. Italy Penile Cancer, by Cause USD Million (2019-2024)
  • Table 270. Italy Penile Cancer, by Grade USD Million (2019-2024)
  • Table 271. United Kingdom Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 272. United Kingdom Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 273. United Kingdom Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 274. United Kingdom Penile Cancer, by Cause USD Million (2019-2024)
  • Table 275. United Kingdom Penile Cancer, by Grade USD Million (2019-2024)
  • Table 276. Netherlands Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 277. Netherlands Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 278. Netherlands Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 279. Netherlands Penile Cancer, by Cause USD Million (2019-2024)
  • Table 280. Netherlands Penile Cancer, by Grade USD Million (2019-2024)
  • Table 281. Rest of Europe Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 282. Rest of Europe Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 283. Rest of Europe Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 284. Rest of Europe Penile Cancer, by Cause USD Million (2019-2024)
  • Table 285. Rest of Europe Penile Cancer, by Grade USD Million (2019-2024)
  • Table 286. MEA Penile Cancer, by Country USD Million (2019-2024)
  • Table 287. MEA Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 288. MEA Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 289. MEA Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 290. MEA Penile Cancer, by Cause USD Million (2019-2024)
  • Table 291. MEA Penile Cancer, by Grade USD Million (2019-2024)
  • Table 292. Middle East Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 293. Middle East Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 294. Middle East Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 295. Middle East Penile Cancer, by Cause USD Million (2019-2024)
  • Table 296. Middle East Penile Cancer, by Grade USD Million (2019-2024)
  • Table 297. Africa Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 298. Africa Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 299. Africa Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 300. Africa Penile Cancer, by Cause USD Million (2019-2024)
  • Table 301. Africa Penile Cancer, by Grade USD Million (2019-2024)
  • Table 302. North America Penile Cancer, by Country USD Million (2019-2024)
  • Table 303. North America Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 304. North America Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 305. North America Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 306. North America Penile Cancer, by Cause USD Million (2019-2024)
  • Table 307. North America Penile Cancer, by Grade USD Million (2019-2024)
  • Table 308. United States Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 309. United States Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 310. United States Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 311. United States Penile Cancer, by Cause USD Million (2019-2024)
  • Table 312. United States Penile Cancer, by Grade USD Million (2019-2024)
  • Table 313. Canada Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 314. Canada Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 315. Canada Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 316. Canada Penile Cancer, by Cause USD Million (2019-2024)
  • Table 317. Canada Penile Cancer, by Grade USD Million (2019-2024)
  • Table 318. Mexico Penile Cancer, by Diagnostic Test Type USD Million (2019-2024)
  • Table 319. Mexico Penile Cancer, by Penile Cancer Type USD Million (2019-2024)
  • Table 320. Mexico Penile Cancer, by Therapy Type USD Million (2019-2024)
  • Table 321. Mexico Penile Cancer, by Cause USD Million (2019-2024)
  • Table 322. Mexico Penile Cancer, by Grade USD Million (2019-2024)
  • Table 323. Research Programs/Design for This Report
  • Table 324. Key Data Information from Secondary Sources
  • Table 325. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Penile Cancer: by Diagnostic Test Type USD Million (2013-2018)
  • Figure 5. Global Penile Cancer: by Penile Cancer Type USD Million (2013-2018)
  • Figure 6. Global Penile Cancer: by Therapy Type USD Million (2013-2018)
  • Figure 7. Global Penile Cancer: by Cause USD Million (2013-2018)
  • Figure 8. Global Penile Cancer: by Grade USD Million (2013-2018)
  • Figure 9. South America Penile Cancer Share (%), by Country
  • Figure 10. Asia Pacific Penile Cancer Share (%), by Country
  • Figure 11. Europe Penile Cancer Share (%), by Country
  • Figure 12. MEA Penile Cancer Share (%), by Country
  • Figure 13. North America Penile Cancer Share (%), by Country
  • Figure 14. Global Penile Cancer share by Players 2018 (%)
  • Figure 15. Global Penile Cancer share by Players (Top 3) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline (United States) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United States) Revenue: by Geography 2018
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 21. MercK & Co (United States) Revenue, Net Income and Gross profit
  • Figure 22. MercK & Co (United States) Revenue: by Geography 2018
  • Figure 23. Mevion Medical Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mevion Medical Systems, Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Varian Medical Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Varian Medical Systems, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Global Penile Cancer: by Diagnostic Test Type USD Million (2019-2024)
  • Figure 30. Global Penile Cancer: by Penile Cancer Type USD Million (2019-2024)
  • Figure 31. Global Penile Cancer: by Therapy Type USD Million (2019-2024)
  • Figure 32. Global Penile Cancer: by Cause USD Million (2019-2024)
  • Figure 33. Global Penile Cancer: by Grade USD Million (2019-2024)
  • Figure 34. South America Penile Cancer Share (%), by Country
  • Figure 35. Asia Pacific Penile Cancer Share (%), by Country
  • Figure 36. Europe Penile Cancer Share (%), by Country
  • Figure 37. MEA Penile Cancer Share (%), by Country
  • Figure 38. North America Penile Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (United States)
  • Novartis AG (Switzerland)
  • MercK & Co (United States)
  • Mevion Medical Systems, Inc. (United States)
  • Varian Medical Systems, Inc. (United States)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Bristol-Myers Squibb Company (United States) , F. Hoffmann-La Roche Ltd (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation